This trial is evaluating whether Tocilizumab will improve 1 primary outcome and 5 secondary outcomes in patients with Adenocarcinoma. Measurement will happen over the course of Up to 12 months.
This trial requires 68 total participants across 5 different treatment groups
This trial involves 5 different treatments. Tocilizumab is the primary treatment being studied. Participants will be divided into 5 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
This chapter addresses the treatments that are approved for both lung adenocarcinoma and adenocarcinoma of other organs. The treatments are very similar for the two types of cancer.
Adenocarcinoma represents a large portion (25%) of lung cancer diagnoses in the United States. Efforts to increase its detection may not only reduce the number of deaths from lung cancer, but may improve the quality of care that patients receive.
Many of the signs are subjective; you may feel that a lump in your breast is too large and painful to be an adenocarcinoma. The most reliable sign of adenocarcinoma is a lump at the mammogram site. [Nipple discharge] is another sign of adenocarcinoma. These symptoms are most similar to infection or breast cancer. [Signs of infection]. There are many [cancerous tumors] associated with [the breast] but do not present with similar characteristics. [Skin tag] are very similar to [cancer], however they present with a different type of presentation. There is a high [grade] of [malignancy] associated with breast adenocarcinoma.
Adenocarcinoma is a neoplasm (cancer) that affects glandular cells in the lung. It is the most common form of lung cancer in both females and males. Adenocarcinoma forms a large proportion (50%) of lung cancer worldwide. It is also the most common site of lung cancer in the US. The presence of an adenocarcinoma affects patients' ability to respire (breathe). It also has a low survival rate after completion of treatment.
Adenocarcinoma can be cured in most cases, but there is considerable risk as to recurrence. The number of cases that are cured is high; the risk can be minimized as much as possible through careful preoperative patient selection, complete surgical excision, postoperative adjuvant chemotherapy, and follow-up care.
In a prospective cohort of people receiving tocilizumab for treatment of rheumatoid arthritis, there was evidence of a safety signal with increased rates of SJS/TEN or, very rarely, the SJS/TEN syndrome in both adults and children. At 6 months, there was an increase in hepatitis B reactivation. The most serious adverse event was liver injury; only one case had been reported by 31 September 2015. Toxicity was generally mild and similar to historical non-chemotherapy controls. All cases were attributed to the use of tocilizumab, and no cases were directly attributable to the drug itself.
The development in the field of drug therapy for inflammatory bowel disease has seen the introduction of several new drug classes; the monoclonal antibodies. Tocilizumab has been shown to reduce intestinal inflammation, thus slowing down the disease progression in IBD patients, improving the physical and social function of patients with moderate-to-severe disease activity. Clinical trials have confirmed the safety and efficacy of treatment. It has been approved in the United States in November 2012 for use as an add-on treatment in adults with moderate-to-severe Crohn's disease who fail standard of care therapy, with or without a fistulizing Crohn's disease modifier.
Although tocilizumab is not an effective treatments to treat the symptoms and outcomes of patients with advanced cancer, it can reduce the complications and shorten the duration of chemotherapy, thus alleviating the treatment-associated side effects on the patients, and improving their quality of life.\n
Commonly reported side effects associated with tocilizumab monotherapy or combination therapy include injection site reactions, fatigue, headache, nausea, and abdominal pain. Although a causal relationship connecting tocilizumab exposure to these events can not be determined, patients should be warned about these side effects as they occur in more than a third of patients. If patients experience these events, they should seek immediate medical attention.
Compared to a placebo, TIVAE seems to result in similar improvement of patients with symptomatic advanced adenocarcinoma of the pancreas in overall survival or in those in a high performance status. The improvement of symptoms seems associated with a longer survival. Better results might be achieved in patients with a high CD8+ T-lymphocyte count.